RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Investor Presentation (January 2018)

39 slides from RespireRx Pharmaceuticals's investor presentation, Jan 8, 2018

  1. Slide 1: Medicines for Respiratory Diseases

    Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO Medicines for Respiratory Diseases

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements ow) The matters discussed in this presentation that are not historical facts are "forward- looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and we intend that such forward-looking sta

  3. Slide 3: Breath is the universal factor of life (quote)

    "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." ort Abbot George Burke

  4. Slide 4: Innovative Medicines for Respiratory Diseases: Corporate Overview

    Innovative Medicines for Respiratory Diseases R\Resp pireRx Pharmaceuticals Inc Corporate Overview Focused on the development of novel medicines to treat very large respiration-related diseases with no pharmaceutical treatments: sleep apnea/hypopnea, respiratory depression and respiratory distress V

  5. Slide 5: Apneas: Types, Their Measurement, Epidemiology and Economics

    Apneas: Types, Their Measurement, Epidemiology and Economics RespireRx Pharmaceuticals Inc

  6. Slide 6: Types of Sleep Apnea

    3 Types of Sleep Apnea Obstructive (OSA) - a peripheral phenomenon that occurs when throat muscles intermittently relax and block airway during sleep May be accompanied by snoring Central (CSA) — a brain-mediated phenomenon that occurs when breathing control centers in the brain reduce activity Freq

  7. Slide 7: Sleep Apnea and its Measurement

    Sleep Apnea and its Measurement A) Resp ireRx ¢ Apnea: Cessation of breathing for > 10 seconds ¢ Hypopnea: Abnormal, severe slowing of breathing for > 10 seconds ¢ Apnea - Hypopnea Index (AHI): Average number of apnea- hypopnea events per hour during sleep (indicator of the severity of sleep apnea)

  8. Slide 8: OSA Afflicts Nearly 30 Million People in the US

    OSA Afflicts Nearly 30 Million People in the US . and There Are No Approved Medicines for OSA RespireRx Pharmaceuticals Inc IS Adult Population 245.2 MM Prevalence of OSAS (AHI>5) 29.4 MM Diagnosed Undiagnosed Oral Appliances Source: U.S. Census 2014) Am J Epidemiol, 2013 May 1;177(9)1006-14. do: 10

  9. Slide 9: The Economic Impact of OSAS in the US is $162 Billion

    The Economic Impact of OSAS in the US is $162 Billion WNW RespireRx respiren Inc Only 20% of Sleep Apnea Patients are Diagnosed ae ™ Diagnosed/Treated 5.9 MM Patients $12.4 B ™ Undiagnosed/Untreated 23.5 MM People $149.6 B ‘Source: Am J Epidemiol. 2013 May 1;177(9):1006-14. doi: 10.1093/aje/kws342.

  10. Slide 10: OSA — Costs of the Problem in the US

    OSA — Costs of the Problem in the US GQ RespireRx Pharmaceuticals Inc OSAtS 29.4 Million $162.0 Billion $0 Asthma®7 16.4 Million $18.3 Billion $13.5 Billion Hypertension®1° 43.2 Million $73.4 Billion $48.5 Billion Diabetes" 12 23.5 Million $174 Billion $20.6 Billion Espicom Business Intobgence’s New

  11. Slide 11: Dronabinol: Breakthrough Treatment for Obstructive Sleep Apnea

    Dronabinol: Breakthrough Treatment for Obstructive Sleep Apnea RespireRx Pharmaceuticals Inc ii.

  12. Slide 12: Dronabinol: A Breakthrough Treatment for OSA

    nabinol: A Breakthrough Treatment for OSA Resp ireRx * Dronabinol Background = FDA approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy (Marinol®) = Schedule Ill drug available by prescription, with a low risk of addiction * Intel

  13. Slide 13: Mean % Non-Compliance in Published RCTs

    Pharmaceuticals Inc Mean % NonCompliancein Published RCTs. We ) j y) ALLE ie” J Otolaryngol Head Neck Surg. 2016; 45: 43

  14. Slide 14: The Phase 2B PACE Clinical Trial

    The Phase 2B “PACE” Clinical Trial: Pharmacotherapy of Apnea by Cannabimimetic Enhancement BR RespireRx PACE INVESTIGATORS University of Illinois David W. Carley, PhD Bharati Prasad, MD Hui Xie, PhD Boris Vern, MD, PhD Chengbo Yuan The PACE Clinical Trial was funded by the National Heart, Lung & Blo

  15. Slide 15: Design of The Phase 2B PACE Trial in OSA

    Design of The Phase 2B PACE Trial in OSA AE * Study Design = Six week, double-blind, placebo controlled clinical study in 73 patients with OSA RespireRx Pharmaceuticals Inc * Dosage / Administration Fully funded by = Placebo, 2.5 mg, or 10 mg dronabinol NIH ~$5 Million at night + Patient Randomizati

  16. Slide 16: PACE Clinical Trial: Phase 2B Study Design

    RespireRx i ae Inc THE PACE Clinical Trial: Pharmacotherapy of Apnea by Cannabimimetic Enhancement - A Phase 2B Study » Randomized, Placebo-controlled, Parallel Groups, Multi-site Trial in Patients with Moderate to Severe OSA * Study Drug: Dronabinol (Overencapsulated Marinol®): 2.5 mg or 10 mg QD *

  17. Slide 17: The Phase 2B PACE Trial in OSA: Final Overall Results

    The Phase 2B PACE Trial in OSA: . Final Overall Results eeeaiere = Statistically significant improvement in Primary Outcome Measures > Apnea-Hypopnea Index (AHI) (2.5 and 10 mg)! > ESS Sleepiness Scale (10 mg)? > Overall Patient Satisfaction (10 mg)? 'p<.02 and p<.001, respectively, compared to plac

  18. Slide 18: Results of 6-Week Treatment: Dronabinol Reduces AHI

    Results of 6-Week Treatment: Dronabinol Reduces AHI* WN RespireRx mespiren Inc Positive Effects of Dronabinol vs. Placebo in TOTAL, REM & NREM Sleep Demonstrate Efficacy Change in Apnea/Hypopnea Index i Ls mTST mNREM mREM Po Py it l *P=0.02 cE. hancement -10 i **P-0.001 annablmimetic Pass Placebo 2.

  19. Slide 19: Dronabinol Reduces Daytime Sleepiness

    abinol Reduces Daytime Sleepiness* BR RespireRx respiren Inc Change in Epworth Sleepiness Scale at 3 *p-0.02 “P-0.001 e Placebo 2.5mgiday 10 mgiday Dronabinol Dose pace= a + Primary Endpoint Clinical Trial 19

  20. Slide 20: Dronabinol Improves MWT

    Dronabinol Improves MWT NW RespireRx Pes pihek Inc Change in Mean Wakefulness Testing (MWT) 6 4 +2 +0 +2 74 +6 + 8 Placebo 2.5 mg/day 10 mg/day P, ACE snce mea Tearyesctieropy of Dronabinol Dose Clinical Trial 20

  21. Slide 21: Dronabinol Has an Excellent Safety Profile

    Dronabinol Has an Excellent Safety Profile and Patients are Highly Satisfied With Treatment WN RespireRx Pharmaceuticals Inc TSQM Response: End of Treatment + Average Number of AEs = 4.1+4.0 + Did not differ by Tx group + Most Frequent Verbatim AEs Reported + Sleepiness/Drowsiness (N=25) + Headache

  22. Slide 22: A Clinical View of the PACE Trial Results

    A Clinical View of the Pace Trial Results (A) RespireRx Comments by David Rapoport, MD Professor of Medicine Mount Sinai School of Medicine* “OSA may affect....long term cardiovascular and cerebrovascular health,..... memory loss and progression of Alzheimer Disease biomarkers.” “...dronabinol is ef

  23. Slide 23: Dronabinol — Phase 3 Regulatory Strategy

    Dronabinol — Phase 3 Regulatory Strategy* ®)RespireRx - Meet with FDA during Q1/2018 Finalize the Phase 3 trial plan required for approval - Position dronabinol as a breakthrough medicine - Seek fast track designation Facilitate and hasten the development path * Pending Finance 23

  24. Slide 24: FDA Expedited Approval Opportunities

    FDA Expedited Approval Opportunities for D Preliminary clinical More frequent meetings with FDA scientific support be measured earlier than irreversible morbidity or rrtalit monalty Cannot or Will Not Use CPAP Breakthrough ed Substantial improvement on clinically significant | More wecuent Fon conmu

  25. Slide 25: Dronabinol in the Marketplace: Strategies to Capture the Sleep Market

    nabinol in the Marketplace: Strategies to Capture the Sleep Market WNW RespireRx o Issued Method-of-Use Patents = Expires in 2025 = Pending patent applications to 2030 & beyond o FDA Designations for Market Exclusivity = Fast-Track = Breakthrough = Hatch-Waxman o Develop a “Branded Generic” Formulat

  26. Slide 26: Dronabinol Opportunity

    T ronabinol Opportunity Gd RespireRx Impact on Patient Commercial Potential First medicine available for OSA Ease of Use/Better Patient Compliance Low cost Safe and effective Potential for better cardiovascular outcomes Changes the nature of OSA treatment Broadly expands prescriber base from sleep s

  27. Slide 27: Potential Dronabinol Economics

    Potential Dronabinol Economics A) RespireRx If FDA approves dronabinol for the treatment of OSA: ¢ Initial target market: Mild to moderate OSA patients who are diagnosed but do not use CPAP ¢ 1,770,000 adults (i.e., 30% of 5.9 million diagnosed adults). ° Daily price per pill is $5.00 e Patient comp

  28. Slide 28: Ampakines for Opioid Induced Apneas

    Ampakines for Opioid Induced Apneas 28

  29. Slide 29: The Opioid Epidemic - Prologue

    The Opioid Epidemic - Prologue (A) RespireRx * 11 million Americans take chronic opioids for pain management and 50% of them have central sleep apnea’. * The majority of opioid deaths occur in non-substance abusing patients * Sleep apnea is a primary risk factor for opioid overdose?. * Opioid-induce

  30. Slide 30: Translational Approach to Respiratory Disorders

    Translational Approach to Respiratory Disorders Resp ireRx " Brain’ stem nuclei that regulate breathing contain opiate and AMPA glutamate receptors that inhibit and excite cell activity, respectively = Ampakines act as positive, allosteric modulators of the AMPA-type glutamate receptor to enhance ex

  31. Slide 31: Ampakines Reduce Opioid Induced Respiratory Depression in Phase 2A

    Ampakines Reduce Opioid Induced Respiratory . Depression in Phase 2A Clinical Trials RespireRx Placebo CX717 Placebo Cx1739 1500 mg 900 mg Opioid Induced Respiratory Depression Average Per Cent Change from Baseline Ampakines reduce opioid induced respiratory depression without altering analgesia 31

  32. Slide 32: CX1739: Completed Phase 2A in Sleep Apnea — Single Dose

    CX1739: Completed Phase 2A in Sleep Apnea — Single Dose (AyResp pireRx Pharmaceuticals Inc Design Randomized, double-blind, placebo-controlled study Population 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received either placebo or

  33. Slide 33: Patient Selection: CX1739 More Effective in Mixed and Central Apneas

    RespireRx i ae Inc Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas Obstructive Apneas Mixed Apneas Central Apnea 2 & g 8 Apnea Index (Events/hr) oa SadSsBz Apnea Index (Events/hr) ona ho kh ao Apnea Index (Events/hr) 33

  34. Slide 34: The RespireRx Ampakine Pipeline

    The RespireRx Ampakine Pipeline Treressrecanmakne’ rine | mespiren Inc Compound CX1739 CX717/CX1739 CX717/CX1739 * Pending finance Indication Opioid-induced Apnea Opioid Induced Sleep Apnea* a Spinal Cord Injury Orphan Diseases: Autism, Pompé* Status Phase 2A Phase 2B Phase 2A Pre-Clinical to Clinic

  35. Slide 35: Ampakine Indications and IP

    Ampakine Indications and IP (@Qyitaatae ¢ Targeted Indications = CSA in Chronic opioid patients = Spinal cord injury = Combination formulation with an opioid for treatment of chronic pain ¢ Intellectual Property Protection (owned and licensed) = Issued Composition-of-Matter Patents (expire 2028) = M

  36. Slide 36: Capital Structure and Market Metrics

    Capital Structure and Market Metrics (gaytcadigiye Pharmaceuticals Inc September 30, 2017 ProForma to December 19, 2017 Common Stock (as of November 13, 2017) 2,633,000 Common Stock Equivalents of Convertible Notes 32,000 Common Stock Equivalents of Options and Warrants Granted (excludes 3,102,000 s

  37. Slide 37: Innovative Medicines for Respiratory Diseases: Corporate Overview

    Innovative Medicines for Respiratory Diseases R\Resp pireRx Pharmaceuticals Inc Corporate Overview Focused on the development of novel medicines to treat very large respiration-related diseases with no pharmaceutical treatments: sleep apnea/hypopnea, respiratory depression and respiratory distress V

  38. Slide 38: Management Team and Directors

    Management Team and Directors AQ RespireRx Pharmaceuticals Inc James Manuso, PhD, President, CEO & Vice Chairman * Biotechnology/pharmaceuticals adstry CEO * Formerly served as Chairman and CEO of Astex Pharmaceuticals * Author of over 30 chapters, articles and books on topics including healthcare c

  39. Slide 39: Medicines for Respiratory Diseases

    Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO Medicines for Respiratory Diseases

RespireRx Pharmaceuticals — Investor Presentation (January 2018) on 6ix